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Abstract
Background: Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II
trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with
advanced CRC.
Methods: Frail patients without prior advanced colorectal cancer treatment were included in the study. Definition
of frailty was defined per protocol based on dependency criteria, presence of chronic comorbid pathologies and/or
geriatric features. Main objective: to assess progression-free survival (PFS) rate at 6 months. Treatment consisted of
28-day cycles of orally administered regorafenib 160 mg/day (3 weeks followed by 1 week rest).
Results: Forty-seven patients were included in the study. Median age was 81 years (range 63–89). Frailty criteria:
dependency was observed in 26 patients (55%), comorbidities in 27 (57%) and geriatric features in 18 (38%). PFS
rate at 6 months was 45% (95% confidence interval [CI] 30–60]. Median PFS was 5.6 months (95%CI 2.7–8.4). Median
overall survival (OS) was 16 months (95%CI 7.8–24). Complete response, partial response and stable disease were
observed in one, two and 21 patients respectively (objective response rate 6.4%; disease control rate 51%). Thirty-
nine patients (83%) experienced grade 3–4 adverse events (AEs). The most common grade 3–4 AEs were hypertension
(15 patients; 32%), asthenia (14; 30%), hypophosphatemia (6; 13%); diarrhea (4; 8%), hand-foot-skin reaction (4; 8%).
There were two toxic deaths (4.2%) (grade 5 rectal bleeding and death not further specified). Dose reduction was
required in 26 patients (55%) and dose-delays in 13 patients (28%).
Conclusions: The study did not meet the pre-specified boundary of 55% PFS rate at 6 months. Toxicity observed (83%
patients experienced grade 3 and 4 AEs) preclude its current use in clinical practice on this setting. Disease control rate
and overall survival results are interesting and might warrant further investigation to identify those who benefit from
this approach.
Trial registration: This trial was prospectively registered at EudraCT (2013–000236-94). Date of trial registration: April
9th, 2013.
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Background
CRC is the third most common cancer diagnosis after
lung and breast cancer [1]. About 20% of patients with
CRC have metastatic disease at diagnosis [2, 3] and up
to 50% will have metastases at some point of the disease
[2]. Median age at diagnosis of patients with CRC is 71.
Therefore, a significant percentage of these patients are
elderly and may be frail, due to either their age itself or
comorbid conditions, leading to special vulnerability to
treatment toxicity. Thus, the group of metastatic CRC
patients who are frail comprises a mixture of elderly-
frail patients, frail-non-elderly patients and very old pa-
tients who may be frail without any specific debilitating
illness [4]. A chronologic transitional sequence “pre-frail
to frail” state with a strong biological background has
been advocated [5]. However, there is little consensus on
the definition of frail patients and the limits between the
terms elderly-frail-unfit. A few factors such as ageing,
dependence for performance of daily activities, associ-
ated comorbid conditions, and presence of geriatric fea-
tures (dementia, delirium, frequent falls, incontinence)
are the most important to be taken into account for the
definition of frailty [6].
Treatment of frail and/or elderly patients with ad-
vanced cancer is controversial. Systemic antineoplastic
treatment, although well intentioned, may be too toxic
leading to deterioration of frail cancer patients. These
patients are commonly either totally excluded from par-
ticipation or underrepresented in large pivotal clinical
trials. Thus, the level of scientific evidence is generally
low in this clinical setting and a more speculative ap-
proach is unavoidable for making treatment decisions.
Outcomes achieved with chemotherapy in these patients
with CRC have previously been addressed. Indeed, a ran-
domized clinical trial in elderly and/or frail patients with
metastatic CRC showed that treatment with single agent
fluoropyrimidines resulted in similar efficacy outcomes
and better quality of life, as compared with combination
oxaliplatin-based chemotherapy [7]. In turn, irinotecan-
based combination chemotherapy did not show advan-
tage in terms of progression-free survival (PFS) over
fluoropyrimidines alone in elderly patients [8]. There-
fore, the appropriateness of polychemotherapy to treat
these patients is controversial, and better tolerated regi-
mens such as single agent regimens or new targeted
drugs may be more suitable for treating frail patients.
Regorafenib (BAY 73–4506, Stivarga® Bayer HealthCare
Pharmaceuticals Inc) is an oral multitargeted multikinase
inhibitor with dual antiproliferative and antiangiogenic ac-
tivity. A number of receptors such as VEFGFR1/3, KIT,
TIE-2, PDGFR-β, FGFR-1, RET, RAF1 and B-RAF are the
main targets for regorafenib [9, 10], which is approved for
the treatment of advanced gastrointestinal stromal tumor
(after sequential failure to front-line imatinib and second-
line sunitinib) and pretreated metastatic CRC (after expos-
ure to fluoropyrimidines, anti-VEGF therapy and anti-
EGFR therapy if RAS wild type). Results from the COR-
RECT randomized study [11] showed that, as compared
with placebo, regorafenib prolonged OS in patients with
CRC previously treated with all approved standard therap-
ies (6.4 versus 5.0 months; hazard ratio [HR] 0.77; 95%
confidence interval [95% CI] 0.64–0.94; one-sided p
0.0052). Treatment was well tolerated being hand-foot
skin reaction (HFSR), fatigue and hypertension the most
frequent grade 3 or higher adverse events (AEs).
As the CORRECT study showed activity and manage-
able toxicity for regorafenib single agent, it was reason-
able to investigate this strategy in first-line treatment of
frail patients. Based on this background, this clinical trial
was designed aiming to assess the efficacy and safety of
regorafenib as a single agent in patients with metastatic
CRC who were frail or unfit for chemotherapy.
Methods
Design
This study was designed as an open-label single-arm
pilot phase II clinical trial. The study was approved by
the Spanish Medicines Agency, by the Regional Clinical
Research Ethics Committee of the Community of
Madrid and was performed in accordance with the Good
Clinical Practice guidelines and the last version of the
Declaration of Helsinki (Fortaleza 2013). All patients
provided written informed consent before enrolment.
Patients and treatment
Patients older than 18 with histologically or cytologically
proven advanced colorectal adenocarcinoma, without
major surgery within 28 days prior to the initiation of
study treatment, not previously treated for advanced dis-
ease, with measurable disease according to Response
Evaluation Criteria In Solid Tumors (RECIST) v1.1, and
an Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) ≤ 2, were candidates to be enrolled
in the study. Patients must have been frail and/or not can-
didates to receive combination chemotherapy as defined
by the presence of one or more of the three criteria (a, b,
c) as listed in Table 1. In addition, patients should have ad-
equate organ function, as defined for bone marrow (abso-
lute neutrophil count [ANC] > 1500/mm3; platelets > 100,
000/mm3; hemoglobin > 9 g/dL), renal (creatinine clear-
ance > 30ml/min) and liver (bilirubin < 2.5 times x upper
limit of normal [ULN], alanine aminotransferase [ALT]
and aspartate aminotransferase [AST] < 3 x ULN or < 5 x
ULN if liver metastases were present).
Regorafenib single agent was administered at a dose of
160mg/day (four 40mg tablets) once a day by mouth,
during 21 consecutive days followed by 7 days of rest. This
3 + 1 week schedule makes up a 28-day cycle. Regorafenib
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had to be taken in the morning, with some water after a
light breakfast. Treatment was maintained until disease
progression or unacceptable toxicity, physician discretion
or patient decision for any reason. Dose modifications
were performed in accordance with the Spanish product
label. In summary, for administration of the next cycle, re-
covery of ANC to 1500/mm3 and platelets to 100,000/
mm3 and recovery of the non-hematologic toxicities to
National Cancer Institute Common Terminology Criteria
(NCI-CTC) grade ≤ 2 were required. Grade 3–4 AEs led
to a dose reduction except grade 4 hypertension, which
led to permanent discontinuation. Three dose levels were
established (160mg/day, 120mg/day and 80mg/day) to
make possible dose adjustments. Special management was
required for HFSR, which should have recovered to
grade ≤ 1 before resuming regorafenib and grade 2 or
higher led to dose reduction.
Study procedures
Progression was the main event for calculating the ma-
jority of the time to event variables of the study. This
event in particular, and tumor response in general, was
assessed according to RECIST v1.1 by the investigators.
Image tumor assessments were performed every 8 ± 2
weeks. Both physical exam with blood pressure measure-
ment and blood analysis (complete blood count, liver
function tests, creatinine, albumin, glucose, urea and
phosphorus) were performed weekly during the first two
cycles and every other week thereafter. Assessment of
carcinoembryonic antigen (CEA) was performed every
cycle and test-strip monitoring for proteinuria every two
cycles (if positive, a 24 h urine sample assessment was
mandatory). The AEs were graded according to the
NCI-CTC v4.0.
Statistical analysis
We considered that a 55% PFS rate at 6 months would
be a clinically relevant outcome with regorafenib treat-
ment. Sample size calculation showed that 46 patients
were required to both establish this PFS rate at 6 months
and to reject the null hypothesis (defined as a PFS rate
lower than 35%), with an alpha error of 0.05 and 80%
power. The intention to treat (ITT) population was the
analysis set and included all patients enrolled in the
study who received at least one cycle of treatment and
had at least one efficacy or safety evaluation.
The statistical analyses of the primary objective (PFS
rate at 6 months) as well as the other time to event vari-
ables (duration of response, OS, time to response, time
to progression, and treatment failure) were performed
by the Kaplan-Meier product limit method. Tumor re-
sponse (and other qualitative variables) were described
with frequencies and percentages whereas quantitative
variables were described with mean and/or median and
range.
Results
Patient characteristics
Fifty-five patients were screened and 47 were included
in the study between June 2013 and February 2015 in
13 hospitals in Spain. These patients were part of
both the ITT population and the safety population.
Table 2 summarizes baseline characteristics of pa-
tients. Briefly, median age was 81 years (range 63–89)
and 21 patients (45%) were female. Thirty patients
(64%) had an ECOG-PS 0–1 and 15 patients (32%)
had a primary rectal adenocarcinoma. The most fre-
quent sites of metastases were liver in 31 patients
(66%) and lung in 29 patients (62%). Thirty-one pa-
tients (66%) had previous surgery for the primary
colorectal tumor and seven patients (15%) received
previous adjuvant chemotherapy (four patients had
capecitabine single agent and three oxaliplatin plus
capecitabine). Seventeen patients (36%) had only one
organ involved by metastatic disease. Regarding the
frailty criteria, dependency was observed in 26 pa-
tients (55%), comorbidities in 27 (57%) and geriatric
features in 18 (38%). Twenty patients (42%) fulfilled a
combination of two or three frailty criteria.
Table 1 Frailty criteria
a) Dependency for daily activities due to comorbidities, different to
deterioration from cancer.
b) Previous history of three or more of these comorbidities, even under
control because of a correct treatment:
□ Congestive heart failure
□ Other chronic cardiovascular diseases
□ Chronic obstructive pulmonary disease
□ Cerebrovascular disease
□ Peripheral neuropathy
□ Chronic renal failurea
□ Arterial hypertension
□ Diabetes mellitus
□ Systemic vasculitis
□ Severe arthritis
c) At least one of these geriatric features:
□ Age > 85 years
□ Fecal or urinary incontinence
□ Spontaneous bone fractures
□ Mild or moderate dementia
□ Frequent falls
Patients must be frail and/or not candidates to receive polychemotherapy as
defined by the presence of one or more of the three criteria (a, b, c). aHowever
creatinine clearance should be > 30mL/min for regorafenib treatment
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Efficacy and dose modifications
Median follow-up was 10.7 months. PFS rate at 6
months was 45% (95%CI 30–60) (Fig. 1). Median PFS
was 5.6 months (95%CI 2.7–8.4) (Table 3). Median OS
was 16months (95%CI 7.8–24) (Fig. 1). Response was
not evaluable in 10 patients who discontinued before
first scheduled radiological assessment (4 patients due to
AEs, 4 patient decision and 2 toxic deaths).
Table 2 Patient characteristics and exposure to regorafenib treatment
N = 47
Gender, n %
Male 26 (55)
Female 21 (45)
Age (years), median [range] 81 [63–89]
ECOG PS, n %
0 5 (11)
1 25 (56)
2 17 (36)
Frailty criteria, n %
Dependence for daily activities 8 (17)
History of comorbidities 13 (28)
Geriatric symptoms 6 (13)
Dependence + Comorbidities 8 (17)
Dependence + Geriatric features 6 (13)
Comorbidities + Geriatric Features 2 (4.3)
Dependence + Geriatric Features + Comorbidities 4 (8.5)
Primary tumor site, n %
Colon 32 (68)
Rectum 14 (30)
Both 1 (2.1)
Metastatic at first diagnosis, n % 30 (64)
Metastatic sites, n %
Liver 31 (66)
Lung 29 (62)
Peritoneum 11 (23)
Bone 1 (2.1)
Number of organs involved by M1 disease, n %
1 17 (36)
2 14 (30)
3 12 (25)
4 2 (4.3)
5 2 (4.3)
Prior surgery, n % 31 (66)
Prior radiation therapy, n % 6 (13)
Prior adjuvant chemotherapy, n % 7 (15)
Capecitabine alone 4 (0.8)
Capecitabine-oxaliplatin 3 (0.6)
Exposure to regorafenib
Dose intensity (mg/day), median [range] 91 [58–121]
Relative dose intensity (mg/day/theoretical total dose), % [range] 0.76 [0.48–1.01]
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Fig. 1 Progression free survival and Overall survival
Table 3 Efficacy results
ITT population (N = 47)
Best objective response
Overall response rate, % 6.4
Complete response, n (%) 1 (2.1)
Partial response, n (%) 2 (4.3)
Stable disease, n (%) 21 (45)
Progression disease, n (%) 13 (28)
Disease control rate, n % 24 (51)
Non-evaluable, n % 10 (21)
Progression free survival (months), median (95%CI) 5.6 (2.7–8.4)
Progression free survival, rate at 6 months (95%CI) 45% (30–60)
Overall survival (months), median (95%CI) 16 (7.8–24)
Time to treatment failure (months), median (95%CI) 2.1 (1.3–2.9)
Time to progression (months), median (95%CI) 5.6 (1.9–9.3)
*N = 21 for stable disease analysis; Disease control rate = Overall response rate + stable disease rate
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Complete response and partial response were observed
in one and two patients, respectively, leading to 6.4% ob-
jective response rate in the ITT population. Stable dis-
ease was observed in 21 patients leading to 51% disease
control rate. Response assessment was investigator-
based and not centrally reviewed.
A total of 198 cycles of regorafenib (3 weeks of each 4
week cycle) were administered to 47 patients (mean 4.2
cycles, median 2.0 and range 1–20), and 23 cycles had to
be delayed (12%). Thirteen patients (28%) required one
to four delays. The most common cause of delay was
non-hematologic toxicity (asthenia in 3 cycles, urinary
tract infection in 3 cycles and diarrhea in 2 cycles). Dose
reduction was required in 26 patients (55%) who needed
one (16 out of 26 patients; 61%) or two dose reductions
per patient. The most common cause of dose reduction
was fatigue (12 out 37 cycles; 32%) followed by HFSR
and mucositis (4 cycles each; 11%); hypophosphatemia
and hypertension (2 cycles each; 5.4%). Median relative
dose intensity (mg/day/planned total dose) was 76%
(range 48–101). Among the patients with complete and
partial response, all of them necessitated dose reduction
(only one patient needed two dose reductions), one of
them required dose delays (3 cycles delayed: one for as-
thenia and two for administrative reasons), and the rela-
tive dose intensity among these patients ranged between
83 and 62%.
Safety and post-study treatments
Thirty-nine patients (83%) experienced grade 3–4 AEs.
The most common grade 3–4 AEs were hypertension (15
patients; 32%), asthenia (14; 30%), hypophosphatemia (6;
13%); diarrhea (4; 8%), HFSR (4; 8%), increased AST (3;
6.4%), mucositis 3 (6.4%) (Table 4). Other grade 3–4 AEs
occurred in less than 5% of patients. Grade 3–4 AEs were
observed in 101 out of 198 cycles administered (51%),
mainly in the first two cycles. Twenty-two patients (47%)
experienced serious AEs (SAEs). Among them, 13 patients
(28%) experienced regorafenib-related SAEs. Eleven pa-
tients (23%) discontinued treatment because of toxicity
being the most frequent fatigue. Besides toxicity, the rea-
son for regorafenib treatment withdrawal was death in
three patients (6.4%), intercurrent disease/AE not related
to the treatment in four patients (8.5%), decision of the
patient/investigator in 11 patients (23%), and disease pro-
gression in 18 patients (38%). There were two drug-
related deaths. A fatal rectal primary tumor bleeding oc-
curred during the first cycle at a regorafenib dose of 160
mg/day in an 86-year-old patient. The family decided pal-
liative care and did not authorize blood transfusions or an
invasive approach. The second event was reported in an
84-year-old patient who suffered a sudden death at home
when sleeping, being asymptomatic the previous day, dur-
ing the second cycle at a regorafenib dose of 160mg/day.
Nineteen patients (40%) received second and further
lines of therapy after study treatment discontinuation. The
majority received single agent fluropyrimidine-based treat-
ment. One of the patients treated with capecitabine also
had complete resection of liver metastases. Two patients
received capecitabine-oxaliplatin and one of them was fur-
ther treated with panitumumab-irinotecan. Another pa-
tient received capecitabine-bevacizumab. The range of the
number of post study lines was [1-5] and only two pa-
tients received more than two lines after regorafenib (one
received 3 single-agent treatments and the other one re-
ceived 5 single-agent treatments).
Discussion
This study shows that, when treated with frontline rego-
rafenib, almost half of frail patients with advanced CRC
remain PFS at 6 months and that this treatment resulted
in 16months median OS. Although the study did not
meet the pre-specified boundary of 55% PFS rate at 6
months, median overall survival is remarkable high
when compared with other biologic agents in the same
setting. Indeed, panitumumab resulted in median OS of
12.3 months in a population of frail-elderly patients with
wild-type KRAS tumors [12]. Cetuximab resulted in
11.1 months of median OS in elderly-fit patients [13].
Addition of capecitabine to cetuximab resulted in im-
proved outcomes (median OS 16.1 months) with a
higher skin toxicity, mostly paronychia [14]. Yet, it
should be mentioned that the OS might be affected by
the subsequent treatment lines, and in this study, 40% of
patients received chemotherapy after regorafenib. In
addition, regorafenib resulted in 5.6 months median PFS
which compares favorably with other single agent regi-
mens such as 5-fluorouracil (3.5 months) [7], panitumu-
mab (4.3 months in KRAS wild-type) or cetuximab (2.9
months in RAS non-selected) [13] but seems to be infer-
ior to doublets such as cetuximab-capecitabine (8.4
months in KRAS wild-type) [14] or bevacizumab-
capecitabine (9.1 months) [15]. Regorafenib, like many
targeted tyrosine-kinase inhibitors, lacks at this moment
a specific biomarker [16].
Other different strategies have been addressed in frail
and/or elderly patients. Comparing with fluoropyrimidines-
based chemotherapy, OS with regorafenib in our trial is
clearly longer than the approximately 11months achieved
with fluoropyrimidines (either 5-fluorouracil or capecita-
bine) with or without oxaliplatin in the FOCUS 2 trial [7].
Our OS is in line with results of bevacizumab with capecit-
abine combination as shown in the AVEX randomized trial,
which compared capecitabine-bevacizumab versus capecit-
abine alone resulting in a non-significant difference of 20
versus 16months in median OS [15]. However, an import-
ant difference should be mentioned on the definition of
frailty, which was left to investigator discretion in the AVEX
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trial whereas it was strictly predefined in our study. Re-
sponse rate was low in our trial, as expected, because this is
what is commonly observed with the use of new kinase in-
hibitors [17]. However, a disease control rate of 51% should
be underlined because the clinical value of disease
stabilization is a relevant outcome in metastatic CRC [18].
Furthermore, this benefit may be more valuable in the
group of frail patients due to the fact that, frailty itself has
shown to be an independent factor associated with poor
prognosis in older patients with CRC [19].
After the initiation of our study, two additional trials
performed on similar but pretreated patient population
with CRC, contributed to expanding safety information
available from the CORRECT trial [11]. The REBECCA
study was a phase IV clinical trial [20] and the CONCUR
study was a randomized trial conducted in Asia with the
same design as the CORRECT study [21]. Altogether,
these three trials have defined the pattern of toxicity of
regorafenib with HFSR, hypertension, fatigue and hypo-
phosphatemia being the most frequent AEs. Our results
are in line and show that the safety results should be put
into perspective (i.e. comorbidities, etc.) when adminis-
tered in frontline to frail patients. Like in other studies
[11, 20–23] the percentage of patients who experienced
Table 4 Grade 3–5 adverse events related to regorafenib
Adverse event Grade 3 n (%) Grade 4 n (%) Grade 5 n (%) Total (Grade3–5) n %
Hypertension 14 (30) 1 (2.1) 0 15 (32)a
Fatigue 14 (30) 0 14 (30)
Hypophosphatemia 6 (13) 0 0 6 (13)
HFSRa 4 (8.5) 0 0 4 (8.5)
Diarrhea 4 (8.5) 0 0 4 (8.5)
Increased AST 3 (6.4) 0 0 3 (6.4)
Increased GGT 3 (6.4) 0 0 3 (6.4)
Mucositis 3 (6.4) 0 0 3 (6.4)
Anorexia 2 (4.3) 0 0 2 (4.3)
Increased bilirubin 2 (4.3) 0 0 2 (4.3)
Increased lipase 1 (2.1) 1 (2.1) 0 2 (4.3)
Rectal bleeding 1 (2.1) 0 1 (2.1) 2 (4.3)
Hyperuricemia 0 1 (2.1) 0 1 (2.1)
Sudden death 0 0 1 (2.1) 1 (2.1)
Stroke 1 (2.1) 0 0 1 (2.1)
Pancreatitis 1 (2.1) 0 0 1 (2.1)
Stomathitis 1 (2.1) 0 0 1 (2.1)
Hyperglucemia 1 (2.1) 0 0 1 (2.1)
Skin rash 1 (2.1) 0 0 1 (2.1)
Proteinuria 1 (2.1) 0 0 1 (2.1)
Pancreatitis 1 (2.1) 0 0 1 (2.1)
Nausea 1 (2.1) 0 0 1 (2.1)
Constipation 1 (2.1) 0 0 1 (2.1)
Vaginitis 1 (2.1) 0 0 1 (2.1)
Aphonia 1 (2.1) 0 0 1 (2.1)
Somnolence 1 (2.1) 0 0 1 (2.1)
Dry mouth 1 (2.1) 0 0 1 (2.1)
Abdominal pain 1 (2.1) 0 0 1 (2.1)
Increased ALT 1 (2.1) 0 0 1 (2.1)
Tumor abscess 1 (2.1) 0 0 1 (2.1)
Pneumonia 1 (2.1) 0 0 1 (2.1)
Intestinal perforation 1 (2.1) 0 0 1 (2.1)
a12 out 15 patients (89%) who experienced hypertension, presented hypertension at baseline
Abbreviations: HFSR Hand Foot Skin Reaction
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grade 3 or higher AEs is high, mainly in the first cycle,
but preventable for further cycles by performing dose
modifications. This makes it easier for regorafenib con-
tinuation, thus allowing the patients to obtain the bene-
fits from the treatment [24]. Indeed, in our study, this
idea is clearly underlined by the fact that rate of grade 3
or higher AEs decreases from 83%, when calculated by
patient, to 51% when calculated by cycle. The rate of
SAEs we observed (47%) is higher than that in the COR-
RECT phase II trial (43%) and substantially higher than
the rate of treatment-related SAEs (27%). This may be
due to the nature of a frail population, which may lead
to a need of hospitalization from an AE, in a patient
who otherwise should not need it. We had already ob-
served in our previous study of frontline panitumumab
in elderly-frail patients a 36% SAEs rate [12] which is
higher than that expected for panitumumab single agent.
The overall safety profile we observed calls for a recom-
mendation taking into account that an appropriate fa-
milial and social support is needed in order to prescribe
a treatment with regorafenib in a frail patient. A close
monitoring of patients under treatment is also needed.
For the same reason, an initial treatment dose of 120 mg
daily is a reasonable approach with the possibility of es-
calating if no SAEs and toxicities are observed. A ran-
domized phase 2 study is being conducting to compare
different dose approaches of induction treatment (first
cycle) of regorafenib in metastatic CRC patients. Clini-
calTrials.gov identifier: NCT02835924 [25].
The present study has some limitations. First, firm
conclusions cannot be drawn from a small, single-arm
study and the results should be confirmed in further lar-
ger trials. Second, this study has not an associated phar-
macoeconomic study, which may be a concern when an
innovative and costly treatment is being administered to
frail and/or elderly patients who have competing causes
of death. Third, the absence of a standardized definition
of frailty makes it hard to carry out inter-study compari-
sons. Unfortunately, heterogeneity is very frequent in the
studies conducted in this field, which are being per-
formed on several different types of patients with or
without some, but not all, characteristics of frailty-
elderly-unfit. And fourth, not assessing of quality of life.
Conclusions
In conclusion, the study did not meet the pre-specified
boundary of 55% PFS rate at 6 months. However, after
considering the results of the panitumumab study in frail
patients [12] published in 2015, when the present study
was ongoing, our pre-determined boundary might be
considered too optimistic. Results on disease control rate
and OS provided by regorafenib single agent in this
study are interesting and might warrant further investi-
gation to identify those patients who benefit from this
approach. A higher incidence of grade 3–4 AEs rate as
well as regorafenib dose-reduction and delays rates pre-
clude its current use in clinical practice on this setting.
This suggests that the most appropriate initial dosing
approach for this patient population should be evaluated
further, as well as to define more accurately the sub-
group of frail patients who may derive the maximal
benefit and those patients with an excessive risk of tox-
icity [26]. Investigation on biomarkers must be helpful in
order to achieve these goals.
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